Do you think we can extrapolate the results of TOGETHER-PsA and expect similar results and safety when adding Tirzepatide to another IL-17 inhibitor or to a bDMARD with different mechanism of action?

Yes and no. We don't have hard randomized controlled trial (RCT) data with biologic disease-modifying antirheumatic drugs (bDMARDs) other than ixekizumab at present. However, if we extrapolate data from prior weight loss studies in psoriatic arthritis (PsA) and psoriasis (PsO), it would be reasonabl...

Yes. An abstract presented at the recent EULAR meeting showed the efficacy and safety of GLP-1 agents in combination with other biologics, using a propensity-matched retrospective control group (Venerito et al., EULAR 2026).